# The role of an anti-inflammatory molecule AIM/CD5L in gut ischemia/reperfusion injury of male mice

## TL;DR

This study explores how the anti-inflammatory molecule AIM/CD5L reduces gut reperfusion injury in male mice by inhibiting harmful immune responses.

## Contribution

The study reveals AIM's anti-inflammatory role in gut ischemia/reperfusion injury and its potential as a therapeutic target in males.

## Key findings

- AIM reduces eCIRP-induced pro-inflammatory cytokine production in macrophages.
- AIM increases metabolic activity in macrophages, boosting oxygen consumption and ATP production.
- AIM interacts with eCIRP's receptors TLR4 and TREM-1, potentially blocking harmful signaling.

## Abstract

Resolution of acute gut ischemia causes reperfusion injury, resulting in the release of damage-associated molecular patterns (DAMPs) and tissue injury. A key DAMP, extracellular cold-inducible RNA-binding protein (eCIRP), exacerbates inflammation in reperfusion injury, contributing to organ failure and death. Apoptosis inhibitor of macrophage (AIM or CD5L) is a glycoprotein secreted by macrophages which can influence the activity of immune cells. We seek to investigate AIM expression in ischemia/reperfusion (I/R) and elucidate its anti-inflammatory role in macrophages and intestinal epithelial cells.

Male mice underwent occlusion of the superior mesenteric artery for 60 min, followed by reperfusion for 4 h before sample collection. AIM expression in blood and tissue was evaluated by qPCR, Western blot, and ELISA. Primary peritoneal macrophages from male mice, IEC-6 intestinal epithelial cells, and RAW 264.7 macrophages were stimulated with recombinant mouse (rm) CIRP (denoted eCIRP) and treated with rmAIM. Cytokine levels were assessed by ELISA and qPCR. Metabolic function was measured in macrophages using the Agilent Seahorse XF Pro analyzer. Interactions involving AIM, eCIRP, and eCIRP’s receptors, Toll-like receptor 4 (TLR4) and triggering receptor expressed on myeloid cells-1 (TREM-1), were elucidated by in silico approaches.

Pulmonary AIM mRNA expression decreased by 55.9% (p = 0.018), and protein levels decreased by 26.9% (p = 0.032) in gut I/R mice compared to sham mice. Plasma AIM concentration decreased by 22.0% (p = 0.0362) in gut I/R mice compared to sham. eCIRP treatment increased pro-inflammatory cytokine production by macrophages and intestinal epithelial cells. This increase was significantly attenuated by co-treatment with rmAIM. Macrophages also increased basal oxygen consumption rate by 66.7% and ATP production by 70.3% when treated with rmAIM compared to eCIRP stimulation alone (p < 0.0001). Computational modeling predicted strong interactions between AIM and eCIRP’s receptors, TLR4 and TREM-1, and showed that the presence of AIM altered eCIRP’s binding to these receptors.

In male mice, gut I/R decreases AIM protein levels and mRNA expression in the lungs as well as AIM plasma concentration. AIM reduces eCIRP-induced pro-inflammatory cytokine production in macrophages, potentially by inhibiting eCIRP’s binding to TLR4 and TREM-1. These findings suggest AIM is a promising therapeutic candidate in males with gut I/R.

The online version contains supplementary material available at 10.1186/s10020-025-01385-1.